Paris, France - Although the B-cell depleter rituximab (Rituxan, MabThera; Genentech/IDEC) is not yet marketed for use in the treatment of autoimmune diseases, it is already being used off label in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback